Dexamethasone Downregulates BCRP mRNA and Protein Expression in Breast Cancer Cell Lines
Abstract:It is hypothesized that anti-inflammatory drugs regulate breast cancer resistance protein (BCRP) expression. Hence, we examined the effects of indomethacin and dexamethasone on BCRP expression in MCF cells. For evaluation of BCRP mRNA expression, relative quantitative PCR and comparative Ct method was exploited. BCRP protein expression was measured flow cytometrically with the monoclonal antibody (mAb) BXP-21. Dexamethasone showed a dose-independent and a time-dependent effect on decreasing the mRNA level of BCRP gene in comparison with control in MCF-7 and MCF-7/MX breast cancer cell lines, whereas no changes were noted in the presence of indomethacin. The level of BCRP protein, expressed as a ratio of the corresponding control, was decreased in dexamethasone-treated MCF-7/MX cells. These results could be of great importance when combination therapy protocols with cytotoxic agents and dexamethasone regimens are considered in breast cancer patients.
Document Type: Research Article
Publication date: January 1, 2009
More about this publication?
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.